January 22nd 2024
Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.
Expert oncologists discuss the progression treatment landscape in AL amyloidosis and agents of investigation.
January 15th 2024
Dr. Kumar discusses strategies for managing adverse events in patients with AL amyloidosis.
Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.
January 8th 2024
Dr. Zonder discusses the safety profile of birtamimab in the VITAL study and the clinical implications.
Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.
Expert oncologist Dr. Kumar provides his assessment of unmet needs in AL Amyloidosis, particularly patients with cardiac involvement.
Dr. Zonder discusses the current treatment landscape in AL amyloidosis, highlighting recent advances.
December 20th 2023
Dr. Kumar discusses best practices for accurately and prompt diagnosing AL amyloidosis as well as navigating differential diagnosis.
Expert oncologists Dr. Jeffrey Zonder and Dr. Shaji Kumar discuss AL amyloidosis background, typical patient profiles, and disease staging and risk stratification.
January 17th 2023
The panel closes their discussion by highlighting unmet needs in the multiple myeloma treatment landscape and sharing advice for physicians and patients.
Krina Patel, MD, explains the treatment options for patients with early relapsed multiple myeloma.
January 10th 2023
Jenny Ahlstrom, a patient with multiple myeloma, shares considerations for patients going through treatment, including toxicities, follow-up, and travel planning.
Shaji Kumar, MD, and Krina Patel, MD, discuss the treatment options for patients with newly-diagnosed multiple myeloma who are not eligible for stem cell transplant.
January 3rd 2023
Dr Krina Patel discusses updates in the treatment of newly-diagnosed from recent meetings how the appropriate treatments are selected in patients with newly-diagnosed multiple myeloma.
Dr Shaji Kumar reviews clinical trial data on the role of stem cell transplant as a treatment for newly-diagnosed multiple myeloma in tandem with a multi-agent combination therapy.
December 22nd 2022
Shaji Kumar, MD, reviews the results of the phase 3 study evaluating the use of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
December 19th 2022
Krina Patel, MD, details the three- and four-drug regimen first-line treatment options for transplant-eligible newly-diagnosed multiple myeloma and how to make an appropriate treatment decision.
Shaji Kumar, MD, provides an overview of multiple myeloma, and Jenny Ahlstrom, a patient with multiple myeloma, shares the story of her diagnosis and the resources she used to educate herself.
August 24th 2022
Shaji Kumar, MD and Jonathan Kaufman, MD, discuss unmet needs in the multiple myeloma treatment landscape and share their insights on testing for biomarkers.